Navigation Links
Takeda Responds to FDA Advisory Committee Recommendation
Date:7/14/2010

nd other public health matters. The FDA frequently convenes its panel of outside experts to provide guidance and recommendations; however, the recommendations of the committee are not a final decision. The FDA will evaluate the committee's decision and their final recommendations will follow.

Takeda remains committed to ACTOS and to the millions of people living with type 2 diabetes. Takeda is the inventor and developer of ACTOS, which was launched commercially in the U.S. in 1999. ACTOS, as labeled, is an effective and appropriate treatment option for many people living with type 2 diabetes. Since its launch, more than 100 million ACTOS family prescriptions have been written, covering more than 10 million patients. In clinical trials using ACTOS in monotherapy, the most common adverse events (greater than or equal to 5%) were upper respiratory tract infection, headache, sinusitis, myalgia, tooth disorder, aggravated diabetes mellitus, and pharyngitis.

About ACTOS® (pioglitazone HCl) Indications and Usage

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS has been studied as a monotherapy and in combination with sulfonylurea, metformin, or insulin.

Important Safety Information

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause new, or worsen, heart failure. Patients should talk to their doctor immediately if they experience unusually fast weight gain, fluid retention (swelling), shortness of breath, or unusual tiredness.

ACTOS is not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis.

ACTOS may cause low blood sugar when taken in combination with insulin
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Ill. , May 21, 2013 Reaching ... approval process, the National Association of Boards of Pharmacy ... operate the .PHARMACY domain suffix has passed the Internet ... NABP intends to launch the .PHARMACY gTLD by the ... available to legitimate online pharmacies and related entities that ...
(Date:5/21/2013)... May 21, 2013 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China and the parent of ... for the first quarter ended March 31, 2013 [1] ... Total net revenue, which consists of net revenues generated ...
(Date:5/21/2013)... , May 21, 2013  NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced that it has entered into ... and in-center products to DaVita, the kidney care division ... ) For the use of products ... , NxStage has executed a second amended and ...
Breaking Medicine Technology:NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 2NABP's .PHARMACY Proposal Passes Initial ICANN Evaluation 3Concord Medical Reports First Quarter 2013 Financial Results 2Concord Medical Reports First Quarter 2013 Financial Results 3Concord Medical Reports First Quarter 2013 Financial Results 4Concord Medical Reports First Quarter 2013 Financial Results 5Concord Medical Reports First Quarter 2013 Financial Results 6Concord Medical Reports First Quarter 2013 Financial Results 7Concord Medical Reports First Quarter 2013 Financial Results 8Concord Medical Reports First Quarter 2013 Financial Results 9Concord Medical Reports First Quarter 2013 Financial Results 10Concord Medical Reports First Quarter 2013 Financial Results 11Concord Medical Reports First Quarter 2013 Financial Results 12Concord Medical Reports First Quarter 2013 Financial Results 13NxStage Announces New Agreements with DaVita 2
... (Nasdaq: REGN ) will webcast its presentation at the ... Tuesday, May 10, 2011 at 9:20 a.m. Pacific Time (12:20 ... Company,s web site, www.regeneron.com , on the Investor Relations ... after the live webcast through May 27, 2011.   ...
... Vertical Health Solutions, Inc. (OTCQB: VHSLD) announced that it ... that the Financial Industry Regulatory Authority has approved a ...  The stock ticker change has gone into effect for ... note that the "D" will be removed from the ...
Cached Medicine Technology:Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change 2
(Date:5/21/2013)... 2013 The University of Colorado’s Anschutz ... HEALTHY DINING to help Coloradans make healthier choices when ... program is called HEALTHY DINING IN COLORADO. More ... participating in Colorado. Restaurants will offer a selection of ... lean protein, vegetables, fruits, whole grains and unsaturated fats. ...
(Date:5/21/2013)... Springs, CO (PRWEB) May 22, 2013 ... plan for better nutrition--from farmers' markets filled with whole ... consumers make the most of the season the nutrition ... a healthier lifestyle not to miss. , 1. Eating ... weather that invites shoppers to linger and explore, spring ...
(Date:5/21/2013)... 2013 Swimsuit season is almost here. The ... products has begun with a 35% discount. , Cellulite forms ... women get the dreaded cellulite even if they are in ... where they have been stored as toxic lymph and smashed ... fixes, a specific program that works to dissolve the toxins ...
(Date:5/21/2013)... Bradley, Illinois (PRWEB) May 21, 2013 ... living community], a BMA affordable assisted living community, is hosting ... Don'ts of Arthritis at 2 p.m. on Tuesday, May 28. ... in Dwight, Illinois, serves older adults of all incomes, including ... independence. , The Arthritis program is open to the public. ...
(Date:5/21/2013)... Feed additives have now become an essential part ... of the feed additives are used in micro quantities ... There are variety of feed additives available that are ... type of animal and feed. Nutritional feed additives are ... to the animal in order to gain lean meat ...
Breaking Medicine News(10 mins):Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 2Health News:Colorado Takes a Huge Step toward Transforming the Family Dining Experience 3Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 2Health News:Brilliant Nutrition Offers 5 Ways to Live Healthier and Inspired this Spring 3Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 2Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 3Health News:Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com 4
... seem to be obstinate, as scientists have discovered, as ... result, they are extremely// difficult to annihilate. In fact ... cells, warn researchers from the University of California, Los ... tendency of stem cells that get radiation resistant and ...
... Tuesday said the government was keen to interact with leaders ... India.// ,According to him, a sense of ... year had led to the growth of the disease in ... number of discussions with minority leaders of Uttar Pradesh and ...
... is made possible by Colonoscopy. More patients are willing to ... in// the bud at the very onset. ... at Yale University, found that there is a significant rise ... colon cancer in people .This has helped early treatment possible. ...
... a hospital here after he complained of high blood ... was on way to Delhi airport to take a ... of ill health. He was taken to the Escorts ... under observation," said Jugal Sharma, a spokesperson for the ...
... Chan and her colleagues from Dana-Farber Cancer Institute suggests// ... for scientists working on new therapies for colon cancer. ... women’s health, the investigators found that postmenopausal women with ... dying of the disease if they had been taking ...
... Setting an example, all members of the Andhra Pradesh legislative ... ,Chief Minister Y. S. Rajasekhara Reddy, Speaker K. R. Suresh ... parties Monday underwent HIV tests at a medical camp held ... minister said all 295 members of state assembly should undergo ...
Cached Medicine News:Health News:Colonoscopy Aids Early Detection of Colon Cancer 2Health News:Estrogen Study Provides New Hope For Colon Cancer Treatment 2
... These Low Contrast Flip charts contain 5 ... Numbers on each page. Optotype size is 9.5M. ... 1.25%. These flip charts can be used at ... for the same test. Each offers a ...
The PowerLab/4ST is a high-performance recording unit with built-in amplifiers and is suitable for physiology teaching. It has been designed to cover the broad experimental requirements in life scien...
... high-performance data acquisition system suitable for a ... that require up to 8 input channels. ... speeds of up to 200 000 samples ... compatible with instruments, signal conditioners and transducers ...
... In 1992 BioControl introduced the Biomuse, ... and analyzes any type of human bioelectric ... other processor based devices. This unit is ... for a range of applications. BioControl has ...
Medicine Products: